

dewei 德维

DEWEI MEDICAL EQUIPMENT CO.,LTD

Covid-19 (SARS-COV-2) Antigen Rapid Test Cassette

Performance Evaluation Report

dewei 德维

DEWEI MEDICAL started to research and develop Covid-19 (SARS-COV-2) Antigen Rapid Test Cassette from 2020, and finished three batches in Jul, 2020. According to the guidelines of 《2019 review of new coronavirus antigen / antibody detected tests technology》 and EN13612: 2002, we evaluated the product performance and made the following summary:

1. Intended use

The Antigen Rapid Test Cassette is used for the qualitative detection of SARS-COV-2 infection. The entire detection process takes only 15-20 minutes, and the operation is simple and sensitive. No instruments are required. It can be used for the screening of early infected patients. The Antigen Rapid Test Cassette is an effective supplement for nucleic acid detection.

2. Diagnostic principle

The detection of SARS-COV-2 adopts the principle of double antibody sandwich method and colloidal gold immunochromatography to qualitatively detect SARS-COV-2 antigen in human nasopharyngeal swabs with two highly specific and highly sensitive SARS-COV-2 N antigen monoclonal antibodies, wherein monoclonal antibody I is a capture antibody, fixed in the detection area on the NC membrane, monoclonal antibody II is a colloidal gold-labeled antibody, sprayed on the binding pad, and the NC membrane quality control area C is coated with goat anti-mouse IgG antibody and goat anti-rabbit IgG antibody. The double antibody sandwich method is used in the detection area, and the antigen-antibody reaction is used in the quality control area, combined with colloidal gold immunochromatography technology to detect the SARS-COV-2 in the human body. During detection, the sample is chromatographed under the capillary effect. If the tested sample contains SARS-COV-2, the gold-labeled SARS-COV-2 N antigen monoclonal antibody I combines with SARS-COV-2 to form a complex, and combines with the a SARS-COV-2 N antigen monoclonal antibody II fixed at the detection line during the chromatography process, which will form the "Au-antibody I-N antigen-antibody II" sandwich, so that a purple band appears in the detection area (T); Otherwise, no magenta bands appear in the detection area (T). Regardless of whether there is a SARS-COV-2 antigen in the sample, the complex will continue to be chromatographed up to the control area (C), and a purple band appears when reacting with the goat anti-mouse IgG antibody and goat anti-rabbit IgG antibody. The purple-red band presented in the control area (C) is a standard for judging whether the chromatographic process was successful and serves as an internal control standard for reagents.

3. Physical appearance of Antigen Rapid Test Cassette

Antigen Rapid Test Cassettes were stored sealed and under dry conditions between 2-30°C. Visual inspection of all Antigen Rapid Test Cassettes showed that they were smooth and integrated, without burr, not broken, and not polluted. Migration speed of fluids exceeded ≥ 10 mm/min.

4. Calibration of Antigen Rapid Test Cassette and description of RT-PCR protocol

To calibrate three lots Antigen Rapid Test Cassette (Lot No.: 20200701, 20200702, and 20200703; DEWEI Medical Equipment Co.,Ltd) a confirmation with a RT-PCR kit (Detection Kit for 2109-nCoV (PCR-Fluorescence); Da An Gene Co., Ltd. of Sun Yat-sen University) was used. The SARS-COV-2 genes *N-gene* and *open reading frame 1 ab (ORF1ab)* were used as amplification target genes. *N-gene* probes were labelled with FAM and *ORF1ab* probes were labelled with Yellow to detect the fluorescent signal. Additionally, an endogenous internal control, labelled with Cy5, was used to monitor sample collection, and the RNA extraction- and PCR amplification process, which reduced the occurrence of false negative results. Fluorescence was detected with an Applied Biosystems™ 7500 Dx Real-Time PCR Instrument. A Ct-value >35 was regarded as negative. A total of three positive (P1-3) and five negative controls (N1-5) were blind coded and separate sets of blind coded samples were assigned. Additionally, samples were randomized prior to testing. For each Lot No. testing was repeated three times each over 10 days (30 repeats; **Table 1**). For all three repeats, all Antigen Rapid Test Cassettes of all three Lot No. showed a purple-red band in the control area (C) upon testing, indicating the validity of the chromatographic process and reagents. All positive controls showed an additional band in the detection area (T) for all repeats, indicating the presence of SARS-COV-2.

Table 1. Calibration of three lots of Antigen Rapid Test Cassette. C: Purple-red band appeared in control area. T: additional band appeared in detection area. N1-5: negative controls. P1-3: positive controls. Controls were verified via RT-PCR. No.: Number.

| Control No. | Lot No. 20200701 | | Lot No. 20200702 | | Lot No. 20200703 | |
|-------------|------------------|----|------------------|----|------------------|----|
| | C & T | C | C & T | C | C & T | C |
| P1 | 30 | 0 | 30 | 0 | 30 | 0 |
| P2 | 30 | 0 | 30 | 0 | 30 | 0 |
| P3 | 30 | 0 | 30 | 0 | 30 | 0 |
| N1 | 0 | 30 | 0 | 30 | 0 | 30 |
| N2 | 0 | 30 | 0 | 30 | 0 | 30 |
| N3 | 0 | 30 | 0 | 30 | 0 | 30 |
| N4 | 0 | 30 | 0 | 30 | 0 | 30 |
| N5 | 0 | 30 | 0 | 30 | 0 | 30 |

4. Sensitivity of Antigen Rapid Test Cassette

To evaluate the sensitivity of the Antigen Rapid Test Cassette, a total of 102 Covid-19-positive samples and 116 Covid-19-negative samples were tested via RT-PCR and with all three Lot No. of Antigen Rapid Test Cassette. Nasopharyngeal swabs of Covid-19-positive samples were collected within seven days of symptom onset and Covid-19-negative samples were collected from specimens without a concrete risk of exposure from the Junan Hospital, Tongjiang Hospital, Foshan Women and Children Hospital, and Enping People's Hospital. RNA was extracted using the YHXB kit (Da An Gene Co., Ltd. of Sun Yat-sen University) and 75copies/μL were used for RT-PCR. Samples were blindly labelled by a non-participant and separate sets of blind code were assigned. Additionally, samples were

randomized prior to testing.

The mean Ct-value \pm standard deviation (SD) for RT-PCR-positive samples was 25.74 ± 4.03 and 25.6 ± 4.1 for N-gene and ORF1ab, respectively (**Figure 1**).




Figure 1: Boxplots of the mean Ct-values for the SARS-COV-2 genes open reading frame 1ab (ORF1ab) and N-gene of Covid-19-positive specimen. A total of 102 nasopharyngeal swabs of Covid-19-positive specimen were collected. N-gene and ORF1ab were detected via RT-PCR using fluorescent probes (Detection Kit for 2019-nCoV (PCR-Fluorescence); Da An Gene Co., Ltd. of Sun Yat-sen University). Each dot represents the Ct-value of either N-gene or ORF1ab per sample.

A total of 99 out of 102 specimens were tested positive for COVID-19 via the Antigen Rapid Test Cassette and positive via RT-PCR, however, three specimens were tested false-negative via the Antigen Rapid Test Cassette (**Table 2**). Therefore, the detection rate (sensitivity; positive percent agreement) and accuracy (overall percentage agreement) for the Antigen Rapid Test Cassette was calculated as follows:

$$\text{Detection rate} = 99/102 \times 100\% = 97.06\% \text{ (95\% CI: 93.78\% - 99.99\%)}$$

$$\text{Accuracy} = (99+113) / (102+116) \times 100\% = 97.25\% \text{ (95\% CI: 96.14\% - 98.36\%)}$$

Table 2: Comparison of Covid-19 detection rate via Antigen Rapid Test Cassette and RT-PCR. The SARS-COV-2 genes N-gene and ORF1ab were used. A Ct value > 35 was regarded as negative for Covid-19.

| Antigen Rapid Test Cassette | RT-PCR | | Total |
|-----------------------------|----------|----------|-------|
| | positive | negative | |
| positive | 99 | 3 | 102 |
| negative | 3 | 113 | 116 |
| Total | 102 | 116 | 218 |

A correlation analysis of antigen-positive/PCR-positive and antigen-negative/PCR-positive samples was performed in RStudio® (version 3.6.3) using the CRAN-package “lrm”. As the antigen test is naturally a dichotomous variable (positive or negative), an antigen-positive outcome was set to “1” and an antigen-negative outcome was set to “0”. A point-biserial correlation value was correlated using the function “biserial.cor”. However, no point-biserial correlation for both N-gene and ORF1ab with correlation values of 0.032 and 0.028, respectively was detected.

Further, the detection rate of the Antigen Rapid Test Cassette was evaluated in relation to the Ct-values of N-gene and ORF1ab for the 102 RT-PCR-Covid-19-positive samples (**Figure 2**). Of antigen-positive samples the lowest detected Ct-value of N-gene was 16.5 for sample D2078, while the highest detected Ct-value was 34.5 for sample D2101. The minimum detected Ct-value for ORF1ab was 16 for sample D2078 and the maximum Ct-value was 34.2 for sample D2101. Of antigen-positive samples 81.6% showed Ct-values for N-gene and ORF1ab between 20.0 and 29.9. Three samples (D2008, D2031, and D2079) were tested positive via RT-PCR, however, negative via the Antigen Rapid Test Cassette. The mean Ct-value \pm SD of these samples was 26.47 ± 0.85 and 26.27 ± 0.85 for N-gene and ORF1ab, respectively.




Figure 2: Histograms of Ct-values for the SARS-COV-2 genes N-gene and ORF1ab in relation to Antigen Rapid Test Cassette. RT-PCR Ct-values of SARS-COV-2 genes **a** N-gene and **b** ORF1ab. White bars represent counts of antigen-positive/RT-PCR-positive samples and black bars antigen-negative/RT-PCR-positive samples. Bin width was set to 10.

5. Specificity of Antigen Rapid Test Cassette

A total of 116 specimens without a concrete risk of exposure were tested via a nasopharyngeal swab to evaluate the specificity of the three lots of Antigen Rapid Test Cassettes. Out of the 116 samples, 113 were tested negative with the Antigen Rapid Test Cassette and via RT-PCR. The Ct-value for both N-gene and ORF1ab was >40 for all samples. Three samples (D2113, D2123, and D2140) were tested positive with Antigen Rapid Test Cassette but negative via RT-PCR with Ct-values of >40 for both N-gene and ORF1ab. These samples were re-tested via RT-PCR and showed again Ct-values >40 for both N-gene and ORF1ab.

Therefore, the specificity (negative percentage agreement) was calculated as follows:

$$\text{Specificity} = 113/116 \times 100\% = 97.41\% \text{ (95\% CI: 94.52\% - 99.99\%)}$$

6. Cross-reactivity and interference of Antigen Rapid Test Cassette with other pathogens than SARS-COV-2

Cross-reactivity and interference of all three lots of Antigen Rapid Test Cassettes was evaluated by testing 25 viruses and 13 bacteria. Amongst them were the human Corona virus strains 229E, HKU1, NL63, and OC43, Influenza A & B, RSV, and *Staphylococcus aureus* (Table 3). No cross-reactivity and interference could be detected for cross-reacting and interfering pathogens, except for a cross-reactivity with the highly homologous (79.6%) Human SARS-CoV nucleoprotein at a test concentration of 25 ng/ml.

Table 3: Cross-reacting and interfering pathogens with Antigen Rapid Test Cassette. N/A: Not applicable.

| Type of virus | Concentration | Cross-reaction / interference |
|---|---|-------------------------------|
| Adenovirus Type 3 | 2.0 X 10 ^{6.5} TCID ₅₀ /ml | Not detected |
| Adenovirus Type 7 | 2.0 X 10 ^{4.75} TCID ₅₀ /ml | Not detected |
| Echovirus 2 | 1.0 X 10 ^{6.5} TCID ₅₀ /ml | Not detected |
| Echovirus 11 | 2.0 X 10 ^{5.25} TCID ₅₀ /ml | Not detected |
| Human coronavirus strain 229E | 1.51 X 10 ^{6.0} TCID ₅₀ /ml | Not detected |
| Human coronavirus strain HKU1 | 10 µg/ml | Not detected |
| Human coronavirus strain NL63 | 1.7 X 10 ^{5.0} TCID ₅₀ /ml | Not detected |
| Human coronavirus strain OC43 | 8.9 X 10 ^{5.0} TCID ₅₀ /ml | Not detected |
| Human herpesvirus 1 | 2.0 X 10 ^{6.25} TCID ₅₀ /ml | Not detected |
| Human herpesvirus 2 | 2.0 X 10 ^{4.75} TCID ₅₀ /ml | Not detected |
| Human metapneumovirus 16 Type A1 | 1.06 X 10 ^{6.0} PFU/ml | Not detected |
| Human SARS-coronavirus nucleoprotein | 25 ng/ml | detected |
| Influenza virus A (H1N1) Strain (A/Virginia/ATCC1/2009) | 2.6 X 10 ^{5.0} PFU/ml | Not detected |
| Influenza virus A (H1N1) Strain (A/WS/33) | 5.0 X 10 ^{7.25} TCID ₅₀ /ml | Not detected |
| Influenza virus A(H3N2) Strain (A/Hong Kong/8/68) | N/A | Not detected |
| Influenza virus B Strain (B/ Lee/40) | 2.0 X 10 ^{5.25} TCID ₅₀ /ml | Not detected |
| MERS-coronavirus nucleoprotein | 0.25 mg/ml | Not detected |

| | | |
|-------------------------------------|---|--------------|
| Mumps virus Ag | 2.0 X 10 ^{3.5} TCID ₅₀ /ml | Not detected |
| Parainfluenza Type 1, | N/A | Not detected |
| Parainfluenza Type 2, | | |
| Parainfluenza Type 3 | | |
| Parainfluenza Type 4A | 1.97 X 10 ^{7.0} PFU/ml | Not detected |
| Respiratory syncytial virus type A | 4.22 X 10 ^{5.0} TCID ₅₀ /ml | Not detected |
| Respiratory syncytial virus type B | 5.62 X 10 ^{5.0} TCID ₅₀ /ml | Not detected |
| Rhinovirus A16 | 8.8 X 10 ^{5.0} PFU/ml | Not detected |
| Type of Bacteria | | |
| <i>Escherichia coli</i> | 1.0 X 10 ^{6.0} CFU/ml | Not detected |
| <i>Fusobacterium necrophorum</i> | 1.0 X 10 ^{6.0} CFU/ml | Not detected |
| <i>Hemophilus parahaemolyticus</i> | 1.0 X 10 ^{6.0} CFU/ml | Not detected |
| <i>Klebsiella pneumoniae</i> | 1.0 X 10 ^{6.0} CFU/ml | Not detected |
| <i>Moraxella catarrhalis</i> | 1.0 X 10 ^{6.0} CFU/ml | Not detected |
| <i>Mycobacterium tuberculosis</i> | 10 mg/ml | Not detected |
| <i>Neisseria lactamica</i> | 1.0 X 10 ^{6.0} CFU/ml | Not detected |
| <i>Proteus vulgaris</i> | 1.0 X 10 ^{6.0} CFU/ml | Not detected |
| <i>Staphylococcus aureus</i> | 1.0 X 10 ^{6.0} CFU/ml | Not detected |
| <i>Staphylococcus haemolyticus</i> | 1.0 X 10 ^{6.0} CFU/ml | Not detected |
| <i>Staphylococcus saprophyticus</i> | 1.0 X 10 ^{6.0} CFU/ml | Not detected |
| <i>Streptococcus pyogenes</i> | 1.0 X 10 ^{6.0} CFU/ml | Not detected |
| <i>Streptococcus salivarius</i> | 1.0 X 10 ^{6.0} CFU/ml | Not detected |
| Other substances | | |
| Pooled human nasal wash | N/A | Not detected |

6. Other interfering substances

A total of 41 other interfering substances at various concentrations were tested. None of them showed an interference with the Antigen Rapid Test Cassette (Table 4).

Table 4: Other interfering substances with Antigen Rapid Test Cassette.

| Interfering Substance | Concentration | Interference |
|-----------------------|---------------|--------------|
| Acarbose | 0.03 mg/dL | Not detected |
| Acetylsalicylic acid | 3 mg/dL | Not detected |
| Albuterol | 0.005 mg/dL | Not detected |
| Amoxicillin | 5.4 mg/dL | Not detected |
| Anti-nuclear antibody | >1:40 | Not detected |
| Beclomethasone | 4.79 ng/ml | Not detected |
| Benzocaine | 0.13 mg/ml | Not detected |
| Biotin | 1.2 µg/ml | Not detected |
| Budesonide | 2.76 ng/ml | Not detected |
| Chloroquine phosphate | 0.99 mg/L | Not detected |
| Chlorothiazide | 2.7 mg/dL | Not detected |

| | | |
|------------------------------------|-------------|--------------|
| Chlorpheniramine | 0.08 mg/dL | Not detected |
| Dexamethasone | 0.6 µg/ml | Not detected |
| Diphenhydramine | 0.08 mg/dL | Not detected |
| Ephedrine | 0.1 mg/ml | Not detected |
| Flunisolide | 0.61 µg/ml | Not detected |
| Fluticasone | 2.31 ng/ml | Not detected |
| Glimepiride (Sulfonylureas) | 0.164 mg/dL | Not detected |
| Guaiacol glyceryl ether | 1 µg/ml | Not detected |
| Hemoglobin | 100 mg/L | Not detected |
| Ibuprofen | 21.9 mg/dL | Not detected |
| Icteric (Bilirubin) | 40 mg/dL | Not detected |
| Indapamide | 140 ng/ml | Not detected |
| Ivermectin | 4.4 mg/L | Not detected |
| Lopinavir | 16.4 µg/L | Not detected |
| Menthol | 0.15 mg/ml | Not detected |
| Mometasone | 1.28 ng/ml | Not detected |
| Mucin | 0.50% | Not detected |
| Mupirocin | 10 µg/ml | Not detected |
| Oseltamivir | 0.04 mg/dL | Not detected |
| Oxymetazolin hydrochloride | 15% v/v | Not detected |
| Phenylephrine hydrochloride | 15% v/v | Not detected |
| Rheumatoid factor | 200 IU/ml | Not detected |
| Ribavirin | 26.7 µg /ml | Not detected |
| Ritonavir | 16.4 µg/L | Not detected |
| Sodium chloride with preservatives | 4.44 mg/ml | Not detected |
| Sulfur | 9.23 µg/ml | Not detected |
| Tobramycin | 24.03 µg/ml | Not detected |
| Triamcinolone | 1.18 ng/ml | Not detected |
| Triglycerides | 1.5 mg/L | Not detected |
| Zanamivir | 17.3 µg /ml | Not detected |

7. Limit of Detection of Antigen Rapid Test Cassette

Using a heat-inactivated SARS-COV-2 with a starting concentration of 6µg/ml, the limit of detection of the Antigen Rapid Test Cassette was measured. A total of 20 µl heat-inactivated SARS-COV-2 in dilution reagent were added to the Antigen Rapid Test Cassette mimicking nasopharyngeal swabs. Concentrations of heat-inactivated SARS-COV-2 were 1:100, 1:200, 1:400, 1:800, 1:1600, 1:3200, 1:6400, 1:12800, 1:25600. The experiment was repeated 20 times for each dilution. Samples with dilutions between 1:100 to 1:6400 showed a red-purple band in the control area (C) and detection area (T) in each experiment. At a concentration of 1:12800, four out of 60 Antigen Rapid Test Cassettes showed only one band in the control area (C). At a concentration of 1:25600 50% of Antigen Rapid Test Cassettes showed a band in the control area (C) and detection area (T) (**Table 5**).

Table 5: Limit of Detection of Antigen Rapid Test Cassette. Experiments were conducted with three lot numbers (Lot No.) using a heat-inactivated SARS-COV-2 and repeated 20 times for each lot. Control area (C): purple-red band appears in control area. Detection area (T): band appears in detection area.

| concentration | Lot No. 20200701 | Lot No. 20200702 | Lot No. 20200703 |
|---------------|--|------------------|------------------|
| | Control area (C) / Detection area (T) | | |
| 1:100 | 20/20 | 20/20 | 20/20 |
| 1:200 | 20/20 | 20/20 | 20/20 |
| 1:400 | 20/20 | 20/20 | 20/20 |
| 1:800 | 20/20 | 20/20 | 20/20 |
| 1:1600 | 20/20 | 20/20 | 20/20 |
| 1:3200 | 20/20 | 20/20 | 20/20 |
| 1:6400 | 20/20 | 20/20 | 20/20 |
| 1:12800 | 20/19 | 20/18 | 20/19 |
| 1:25600 | 20/10 | 20/9 | 20/11 |

8. HOOK effect study

The effectiveness of antibodies to form immune complexes was tested using a heat-inactivated SARS-COV-2 at concentrations between 1.0×10^3 TCID₅₀/ml and 1.0×10^6 TCID₅₀/ml. All three lots were tested three times (**Table 7**). A purple-red band appeared in the control area (C) on all tested Antigen Rapid Test Cassettes when only the dilution reagent was added to the test cassette. When adding the heat-inactivated SARS-COV-2 a purple-red band appeared in the control area (C) and in the detection area (T) at all given concentrations. These data indicate that no HOOK effect was detected.

Table 7: HOOK effect of Antigen Rapid Test Cassette. Experiments were conducted with three lot numbers (Lot No.) using a heat-inactivated SARS-COV-2 and repeated three times for each lot. Control area (C): purple-red band appears in control area. Detection area (T): band appears in detection area. dil. reag.: dilution reagent without heat-inactivated SARS-COV-2.

| Concentration | Lot No. 20200701 | | Lot No. 20200702 | | Lot No. 20200703 | |
|--|------------------|-------------|------------------|-------------|------------------|-------------|
| | SARS-COV-2 | dil. reag. | SARS-COV-2 | dil. reag. | SARS-COV-2 | dil. reag. |
| 1.0×10^3 TCID ₅₀ /ml | C: 3 / T: 3 | C: 3 / T: 0 | C: 3 / T: 3 | C: 3 / T: 0 | C: 3 / T: 3 | C: 3 / T: 0 |
| 1.0×10^4 TCID ₅₀ /ml | C: 3 / T: 3 | C: 3 / T: 0 | C: 3 / T: 3 | C: 3 / T: 0 | C: 3 / T: 3 | C: 3 / T: 0 |
| 1.0×10^5 TCID ₅₀ /ml | C: 3 / T: 3 | C: 3 / T: 0 | C: 3 / T: 3 | C: 3 / T: 0 | C: 3 / T: 3 | C: 3 / T: 0 |
| 1.0×10^6 TCID ₅₀ /ml | C: 3 / T: 3 | C: 3 / T: 0 | C: 3 / T: 3 | C: 3 / T: 0 | C: 3 / T: 3 | C: 3 / T: 0 |

9. Conclusion

The Antigen Rapid Test Cassette was compared with RT-PCR and evaluated using 102 symptomatic SARS-COV-2-positive and 116 non-exposed specimens. Samples were taken via nasopharyngeal swabs. The test results show that 99 out of 102 Antigen Rapid Test Cassettes detected an infection with SARS-COV-2, leading to a sensitivity of 97.06%. The overall mean of Ct-values for RT-PCR-positive samples was 25.74 ± 4.03 and 25.6 ± 4.1 for N-gene and ORF1ab, respectively. A correlation analysis showed no correlation between antigen-positive/RT-PCR-positive samples and antigen-negative/RT-PCR-positive samples. A total of 81.6% of antigen-positive/RT-PCR-positive samples showed Ct-values between 20.0 and 29.9 while the mean Ct-value of the three antigen-negative/ RT-PCR-positive samples were 26.47 ± 0.85 and 26.27 ± 0.85 for N-gene and ORF1ab, respectively. Out of 116 SARS-COV-2-negative samples, 113 were detected as negative with the Antigen Rapid Test Cassette, leading to an overall specificity of 97.41%. Except for the highly homologous SARS-CoV nucleoprotein, none of the 38 tested pathogens and 41 substances cross-reacted and interfered with the Antigen Rapid Test Cassette. Notably, other SARS-COV-2 strains, as well as Influenza A & B, and Staphylococcus aureus were tested for cross-reactivity and interference. In conclusion, the test results show that the Paul-Ehrlich-Institute's minimum requirements listed on www.PEI.de (accessed between 25.3.2021 and 29.4.2021) for Rapid SARS-CoV-2 Antigen Tests were met and the DEWEI Antigen Rapid Test Cassette can be utilized as effective supplement for nucleic acid detection to control the COVID-19 pandemic.

10. Appendix table

The DEWEI Antigen Rapid Test Cassette was tested with total of 218 specimens (D2001-D2229; Pat.No) using nasopharyngeal swabs. Non-exposed patients and patients with the clinical diagnosis COVID-19 were tested within seven days of symptoms onset using the Antigen Rapid Test Cassette and two specific genes for SARS-COV-2 (N-gene an ORF1ab). Ct-values were evaluated via RT-PCR: C: purple-red band appears in control area (C) of the Antigen Rapid Test Cassette. T: Band appears in detection area (T). Bold: false-positive or false-negative samples.

| No. | Pat. No. | Gender | Age | Sample Type | Clinical Diagnosis | Antigen Rapid Test Cassette | N-gene Ct-value | ORF1ab Ct-value | Disease Onset Time |
|----------|--------------|----------|-----------|----------------------------|--------------------|-----------------------------|-----------------|-----------------|--------------------|
| 1 | D2001 | M | 42 | Nasopharyngeal Swab | COVID-19 | C/T | 25.4 | 25.1 | 5 days |
| 2 | D2002 | M | 65 | Nasopharyngeal Swab | COVID-19 | C/T | 29.1 | 28.9 | 1 day |
| 3 | D2003 | F | 20 | Nasopharyngeal Swab | COVID-19 | C/T | 21.4 | 21.4 | 3 days |
| 4 | D2004 | F | 38 | Nasopharyngeal Swab | COVID-19 | C/T | 21.5 | 21.0 | 1 day |
| 5 | D2005 | F | 72 | Nasopharyngeal Swab | COVID-19 | C/T | 22.2 | 22.1 | 3 days |
| 6 | D2006 | M | 66 | Nasopharyngeal Swab | COVID-19 | C/T | 24.5 | 24.3 | 2 days |
| 7 | D2007 | F | 37 | Nasopharyngeal Swab | COVID-19 | C/T | 23.2 | 23.3 | 2 days |
| 8 | D2008 | M | 38 | Nasopharyngeal Swab | COVID-19 | C | 27.3 | 27.1 | 4 days |
| 9 | D2009 | M | 20 | Nasopharyngeal Swab | COVID-19 | C/T | 22.8 | 22.6 | 2 days |
| 10 | D2010 | F | 26 | Nasopharyngeal Swab | COVID-19 | C/T | 27.9 | 27.8 | 7 days |
| 11 | D2011 | F | 53 | Nasopharyngeal Swab | COVID-19 | C/T | 23 | 23.0 | 1 day |
| 12 | D2012 | F | 86 | Nasopharyngeal Swab | COVID-19 | C/T | 21.5 | 21.2 | 3 days |
| 13 | D2013 | M | 56 | Nasopharyngeal Swab | COVID-19 | C/T | 23 | 22.2 | 4 days |
| 14 | D2014 | F | 58 | Nasopharyngeal Swab | COVID-19 | C/T | 24.5 | 24.1 | 2 days |
| 15 | D2015 | M | 10 | Nasopharyngeal Swab | COVID-19 | C/T | 23.4 | 23.1 | 3 days |
| 16 | D2016 | M | 34 | Nasopharyngeal Swab | COVID-19 | C/T | 28.2 | 28.2 | 1 day |
| 17 | D2017 | F | 39 | Nasopharyngeal Swab | COVID-19 | C/T | 27.2 | 27.4 | 2 days |
| 18 | D2018 | F | 47 | Nasopharyngeal Swab | COVID-19 | C/T | 22.4 | 22.3 | 2 days |
| 19 | D2019 | F | 61 | Nasopharyngeal Swab | COVID-19 | C/T | 27.5 | 27.3 | 6 days |
| 20 | D2020 | M | 30 | Nasopharyngeal Swab | COVID-19 | C/T | 26 | 25.5 | 4 days |
| 21 | D2021 | F | 15 | Nasopharyngeal Swab | COVID-19 | C/T | 24 | 23.6 | 1 day |

| | | | | | | | | | |
|-----------|--------------|----------|-----------|----------------------------|-----------------|----------|-------------|-------------|---------------|
| 22 | D2022 | F | 47 | Nasopharyngeal Swab | COVID-19 | C/T | 25.2 | 25.1 | 2 days |
| 23 | D2023 | F | 29 | Nasopharyngeal Swab | COVID-19 | C/T | 26.3 | 26.2 | 2 days |
| 24 | D2024 | F | 49 | Nasopharyngeal Swab | COVID-19 | C/T | 27.3 | 27.1 | 2 days |
| 25 | D2025 | F | 43 | Nasopharyngeal Swab | COVID-19 | C/T | 29.8 | 31.2 | 4 days |
| 26 | D2026 | M | 58 | Nasopharyngeal Swab | COVID-19 | C/T | 28.6 | 28.5 | 6 days |
| 27 | D2027 | F | 18 | Nasopharyngeal Swab | COVID-19 | C/T | 24.2 | 24.1 | 2 days |
| 28 | D2028 | F | 13 | Nasopharyngeal Swab | COVID-19 | C/T | 25.3 | 25.2 | 2 days |
| 29 | D2029 | F | 50 | Nasopharyngeal Swab | COVID-19 | C/T | 22.6 | 22.5 | 2 days |
| 30 | D2030 | F | 55 | Nasopharyngeal Swab | COVID-19 | C/T | 24.6 | 24.4 | 1 day |
| 31 | D2031 | M | 48 | Nasopharyngeal Swab | COVID-19 | C | 26.8 | 26.6 | 3 days |
| 32 | D2032 | F | 74 | Nasopharyngeal Swab | COVID-19 | C/T | 26.4 | 26.3 | 4 days |
| 33 | D2033 | F | 36 | Nasopharyngeal Swab | COVID-19 | C/T | 28.5 | 28.1 | 2 days |
| 34 | D2034 | M | 25 | Nasopharyngeal Swab | COVID-19 | C/T | 29 | 29.2 | 4 days |
| 35 | D2035 | F | 34 | Nasopharyngeal Swab | COVID-19 | C/T | 29 | 28.9 | 1 days |
| 36 | D2036 | M | 19 | Nasopharyngeal Swab | COVID-19 | C/T | 26.8 | 26.7 | 2 days |
| 37 | D2037 | F | 28 | Nasopharyngeal Swab | COVID-19 | C/T | 32.5 | 32.8 | 4 days |
| 38 | D2038 | M | 45 | Nasopharyngeal Swab | COVID-19 | C/T | 34.2 | 34.1 | 3 days |
| 39 | D2039 | F | 34 | Nasopharyngeal Swab | COVID-19 | C/T | 26.8 | 26.7 | 2 days |
| 40 | D2040 | M | 55 | Nasopharyngeal Swab | COVID-19 | C/T | 33 | 32.8 | 5 days |
| 41 | D2041 | M | 32 | Nasopharyngeal Swab | COVID-19 | C/T | 34.1 | 34.1 | 3 days |
| 42 | D2042 | F | 22 | Nasopharyngeal Swab | COVID-19 | C/T | 26.8 | 26.7 | 5 days |
| 43 | D2043 | F | 28 | Nasopharyngeal Swab | COVID-19 | C/T | 31.2 | 31.2 | 3 days |
| 44 | D2044 | F | 35 | Nasopharyngeal Swab | COVID-19 | C/T | 29.5 | 29.3 | 4 days |
| 45 | D2045 | M | 56 | Nasopharyngeal Swab | COVID-19 | C/T | 25.4 | 25.3 | 1 days |
| 46 | D2046 | M | 61 | Nasopharyngeal Swab | COVID-19 | C/T | 25.4 | 25.2 | 5 days |
| 47 | D2047 | F | 23 | Nasopharyngeal Swab | COVID-19 | C/T | 24.8 | 24.8 | 2 days |
| 48 | D2048 | F | 21 | Nasopharyngeal Swab | COVID-19 | C/T | 29.5 | 29.4 | 1 day |
| 49 | D2049 | F | 34 | Nasopharyngeal Swab | COVID-19 | C/T | 27.5 | 27.4 | 2 days |

| | | | | | | | | | |
|----|-------|---|----|---------------------|----------|-----|------|------|--------|
| 50 | D2050 | M | 27 | Nasopharyngeal Swab | COVID-19 | C/T | 31.2 | 31.2 | 3 days |
| 51 | D2051 | M | 26 | Nasopharyngeal Swab | COVID-19 | C/T | 25.8 | 25.6 | 3 days |
| 52 | D2052 | F | 56 | Nasopharyngeal Swab | COVID-19 | C/T | 26.6 | 26.5 | 2 days |
| 53 | D2053 | F | 32 | Nasopharyngeal Swab | COVID-19 | C/T | 27 | 26.8 | 5 days |
| 54 | D2054 | F | 27 | Nasopharyngeal Swab | COVID-19 | C/T | 24 | 23.6 | 3 days |
| 55 | D2055 | M | 43 | Nasopharyngeal Swab | COVID-19 | C/T | 25 | 25.2 | 1 days |
| 56 | D2056 | M | 36 | Nasopharyngeal Swab | COVID-19 | C/T | 27 | 26.8 | 2 days |
| 57 | D2057 | F | 43 | Nasopharyngeal Swab | COVID-19 | C/T | 23.8 | 23.6 | 5 days |
| 58 | D2058 | F | 34 | Nasopharyngeal Swab | COVID-19 | C/T | 25.3 | 25.1 | 6 days |
| 59 | D2059 | M | 56 | Nasopharyngeal Swab | COVID-19 | C/T | 27 | 26.8 | 4 days |
| 60 | D2060 | M | 54 | Nasopharyngeal Swab | COVID-19 | C/T | 20.9 | 20.7 | 2 days |
| 61 | D2061 | M | 47 | Nasopharyngeal Swab | COVID-19 | C/T | 26.5 | 26.1 | 3 days |
| 62 | D2062 | F | 46 | Nasopharyngeal Swab | COVID-19 | C/T | 20.5 | 20.2 | 5 days |
| 63 | D2063 | M | 22 | Nasopharyngeal Swab | COVID-19 | C/T | 27.1 | 27.1 | 6 days |
| 64 | D2064 | F | 32 | Nasopharyngeal Swab | COVID-19 | C/T | 22.9 | 22.8 | 2 days |
| 65 | D2065 | M | 48 | Nasopharyngeal Swab | COVID-19 | C/T | 27 | 27.4 | 3 days |
| 66 | D2066 | F | 43 | Nasopharyngeal Swab | COVID-19 | C/T | 30 | 29.7 | 1 days |
| 67 | D2067 | F | 19 | Nasopharyngeal Swab | COVID-19 | C/T | 30.5 | 30.5 | 1 days |
| 68 | D2068 | F | 22 | Nasopharyngeal Swab | COVID-19 | C/T | 30.2 | 30.2 | 2 days |
| 69 | D2069 | M | 76 | Nasopharyngeal Swab | COVID-19 | C/T | 20.5 | 20.1 | 5days |
| 70 | D2070 | M | 75 | Nasopharyngeal Swab | COVID-19 | C/T | 27.7 | 27.7 | 4days |
| 71 | D2071 | F | 82 | Nasopharyngeal Swab | COVID-19 | C/T | 22.8 | 22.7 | 4days |
| 72 | D2072 | F | 66 | Nasopharyngeal Swab | COVID-19 | C/T | 18.3 | 18.2 | 3days |
| 73 | D2073 | M | 56 | Nasopharyngeal Swab | COVID-19 | C/T | 27.5 | 27.2 | 7days |
| 74 | D2074 | F | 59 | Nasopharyngeal Swab | COVID-19 | C/T | 20.3 | 20.2 | 2days |
| 75 | D2075 | F | 68 | Nasopharyngeal Swab | COVID-19 | C/T | 18.7 | 18.5 | 1day |
| 76 | D2076 | F | 62 | Nasopharyngeal Swab | COVID-19 | C/T | 24.3 | 24.2 | 4days |
| 77 | D2077 | M | 83 | Nasopharyngeal Swab | COVID-19 | C/T | 24.3 | 24.0 | 5days |

| | | | | | | | | | |
|-----------|--------------|----------|-----------|----------------------------|----------------------|----------|-------------|-------------|--------------|
| 78 | D2078 | M | 52 | Nasopharyngeal Swab | COVID-19 | C/T | 16.5 | 16.0 | 3days |
| 79 | D2079 | M | 73 | Nasopharyngeal Swab | COVID-19 | C | 25.3 | 25.1 | 3days |
| 80 | D2080 | F | 24 | Nasopharyngeal Swab | COVID-19 | C/T | 18 | 17.8 | 3days |
| 81 | D2081 | F | 59 | Nasopharyngeal Swab | COVID-19 | C/T | 29.8 | 29.5 | 7days |
| 82 | D2082 | F | 66 | Nasopharyngeal Swab | COVID-19 | C/T | 33.5 | 33.9 | 5days |
| 83 | D2083 | F | 36 | Nasopharyngeal Swab | COVID-19 | C/T | 27 | 26.9 | 4days |
| 84 | D2084 | F | 24 | Nasopharyngeal Swab | COVID-19 | C/T | 33.1 | 33.1 | 3days |
| 85 | D2085 | F | 27 | Nasopharyngeal Swab | COVID-19 | C/T | 18 | 17.9 | 6days |
| 86 | D2086 | M | 27 | Nasopharyngeal Swab | COVID-19 | C/T | 20.5 | 20.2 | 2days |
| 87 | D2087 | M | 23 | Nasopharyngeal Swab | COVID-19 | C/T | 20.5 | 20.4 | 4days |
| 88 | D2088 | F | 64 | Nasopharyngeal Swab | COVID-19 | C/T | 16.8 | 16.6 | 3days |
| 89 | D2089 | M | 67 | Nasopharyngeal Swab | COVID-19 | C/T | 22 | 21.7 | 6days |
| 90 | D2090 | F | 32 | Nasopharyngeal Swab | COVID-19 | C/T | 23 | 22.8 | 1day |
| 91 | D2091 | M | 79 | Nasopharyngeal Swab | COVID-19 | C/T | 27.4 | 27.4 | 5days |
| 92 | D2092 | F | 59 | Nasopharyngeal Swab | COVID-19 | C/T | 22 | 22.1 | 4days |
| 93 | D2093 | M | 64 | Nasopharyngeal Swab | COVID-19 | C/T | 24.5 | 24.4 | 5days |
| 94 | D2094 | F | 62 | Nasopharyngeal Swab | COVID-19 | C/T | 26 | 25.6 | 7days |
| 95 | D2095 | F | 63 | Nasopharyngeal Swab | COVID-19 | C/T | 25 | 24.8 | 5days |
| 96 | D2096 | F | 55 | Nasopharyngeal Swab | COVID-19 | C/T | 24.2 | 24.2 | 2days |
| 97 | D2097 | F | 58 | Nasopharyngeal Swab | COVID-19 | C/T | 28 | 27.8 | 4days |
| 98 | D2098 | M | 57 | Nasopharyngeal Swab | COVID-19 | C/T | 16.5 | 16.2 | 7days |
| 99 | D2099 | F | 57 | Nasopharyngeal Swab | COVID-19 | C/T | 31.6 | 31.3 | 3days |
| 100 | D2100 | F | 60 | Nasopharyngeal Swab | COVID-19 | C/T | 30.2 | 30.1 | 4days |
| 101 | D2101 | F | 30 | Nasopharyngeal Swab | COVID-19 | C/T | 34.5 | 34.2 | 6days |
| 102 | D2102 | F | 66 | Nasopharyngeal Swab | COVID-19 | C/T | 31.5 | 31.3 | 5days |
| 103 | D2103 | M | 70 | Nasopharyngeal Swab | Lung Shadow | C | > 40 | > 40 | / |
| 104 | D2104 | M | 39 | Nasopharyngeal Swab | AIDS | C | > 40 | > 40 | / |
| 105 | D2105 | M | 51 | Nasopharyngeal Swab | HIV, Cervical Cancer | C | > 40 | > 40 | / |

| | | | | | | | | | |
|------------|--------------|----------|-----------|----------------------------|---|-----|----------------|----------------|---|
| 106 | D2106 | F | 38 | Nasopharyngeal Swab | Lung Shadow | C | > 40 | > 40 | / |
| 107 | D2107 | M | 65 | Nasopharyngeal Swab | Tuberculosis | C | > 40 | > 40 | / |
| 108 | D2108 | M | 44 | Nasopharyngeal Swab | Tuberculous Meningitis | C | > 40 | > 40 | / |
| 109 | D2109 | M | 22 | Nasopharyngeal Swab | Cough to be tested | C | > 40 | > 40 | / |
| 110 | D2110 | M | 34 | Nasopharyngeal Swab | Tuberculosis | C | > 40 | > 40 | / |
| 111 | D2111 | M | 25 | Nasopharyngeal Swab | Lung Shadow | C | > 40 | > 40 | / |
| 112 | D2112 | M | 25 | Nasopharyngeal Swab | Tuberculosis re-treatment | C | > 40 | > 40 | / |
| 113 | D2113 | M | 56 | Nasopharyngeal Swab | Tuberculosis, Culture-positive | C/T | > 40 | > 40 | / |
| 114 | D2118 | F | 31 | Nasopharyngeal Swab | Fever to be tested | C | > 40 | > 40 | / |
| 115 | D2119 | F | 13 | Nasopharyngeal Swab | Fever to be tested | C | > 40 | > 40 | / |
| 116 | D2120 | M | 54 | Nasopharyngeal Swab | Fever to be tested | C | > 40 | > 40 | / |
| 117 | D2121 | M | 74 | Nasopharyngeal Swab | Fever to be tested, Obsolete Tuberculosis | C | > 40 | > 40 | / |
| 118 | D2122 | M | 75 | Nasopharyngeal Swab | Fever to be tested, | C | > 40 | > 40 | / |
| 119 | D2123 | F | 37 | Nasopharyngeal Swab | Fever to be tested | C/T | > 40 | > 40 | / |
| 120 | D2124 | F | 20 | Nasopharyngeal Swab | Fever to be tested | C | > 40 | > 40 | / |
| 121 | D2125 | F | 69 | Nasopharyngeal Swab | Fever to be tested | C | > 40 | > 40 | / |
| 122 | D2126 | F | 30 | Nasopharyngeal Swab | Fever to be tested | C | > 40 | > 40 | / |
| 123 | D2127 | M | 26 | Nasopharyngeal Swab | Fever to be tested | C | > 40 | > 40 | / |
| 124 | D2128 | F | 38 | Nasopharyngeal Swab | Fever to be tested | C | > 40 | > 40 | / |
| 125 | D2129 | M | 9 | Nasopharyngeal Swab | URTI? | C | > 40 | > 40 | / |
| 126 | D2130 | F | 49 | Nasopharyngeal Swab | COPD with acute exacerbation | C | > 40 | > 40 | / |
| 127 | D2131 | M | 30 | Nasopharyngeal Swab | Skin ulcer of both legs to be tested | C | > 40 | > 40 | / |
| 128 | D2132 | M | 37 | Nasopharyngeal Swab | URTI? | C | > 40 | > 40 | / |
| 129 | D2133 | F | 81 | Nasopharyngeal Swab | Trochanteric fracture of left femur | C | > 40 | > 40 | / |
| 130 | D2134 | M | 72 | Nasopharyngeal Swab | COPD with acute exacerbation | C | > 40 | > 40 | / |
| 131 | D2135 | F | 82 | Nasopharyngeal Swab | Fever to be tested | C | > 40 | > 40 | / |
| 132 | D2136 | F | 89 | Nasopharyngeal Swab | Fever to be tested | C | > 40 | > 40 | / |
| 133 | D2137 | M | 56 | Nasopharyngeal Swab | / | C | > 40 | > 40 | / |

| | | | | | | | | | |
|------------|--------------|----------|-----------|----------------------------|---|-----|----------------|----------------|---|
| 134 | D2138 | M | 38 | Nasopharyngeal Swab | Fever to be tested | C | > 40 | > 40 | / |
| 135 | D2139 | M | 66 | Nasopharyngeal Swab | COPD with acute exacerbation | C | > 40 | > 40 | / |
| 136 | D2140 | M | 60 | Nasopharyngeal Swab | Skin ulcer of both legs to be tested | C/T | > 40 | > 40 | / |
| 137 | D2141 | F | 82 | Nasopharyngeal Swab | Fell and hurt | C | > 40 | > 40 | / |
| 138 | D2142 | F | 39 | Nasopharyngeal Swab | Early Pregnancy Miscarriage | C | > 40 | > 40 | / |
| 139 | D2143 | F | 48 | Nasopharyngeal Swab | AIDS | C | > 40 | > 40 | / |
| 140 | D2144 | M | 64 | Nasopharyngeal Swab | Tuberculosis | C | > 40 | > 40 | / |
| 141 | D2145 | M | 38 | Nasopharyngeal Swab | Lung Shadow | C | > 40 | > 40 | / |
| 142 | D2146 | M | 33 | Nasopharyngeal Swab | Lung Shadow | C | > 40 | > 40 | / |
| 143 | D2147 | M | 80 | Nasopharyngeal Swab | Tuberculosis | C | > 40 | > 40 | / |
| 144 | D2148 | M | 73 | Nasopharyngeal Swab | Tuberculosis | C | > 40 | > 40 | / |
| 145 | D2149 | M | 25 | Nasopharyngeal Swab | AIDS | C | > 40 | > 40 | / |
| 146 | D2150 | F | 54 | Nasopharyngeal Swab | AIDS | C | > 40 | > 40 | / |
| 147 | D2151 | M | 77 | Nasopharyngeal Swab | Tuberculosis | C | > 40 | > 40 | / |
| 148 | D2152 | M | 60 | Nasopharyngeal Swab | AIDS | C | > 40 | > 40 | / |
| 149 | D2153 | M | 25 | Nasopharyngeal Swab | AIDS | C | > 40 | > 40 | / |
| 150 | D2154 | F | 14 | Nasopharyngeal Swab | Cervical and abdominal lymph node TB | C | > 40 | > 40 | / |
| 151 | D2155 | M | 78 | Nasopharyngeal Swab | Lung Shadow | C | > 40 | > 40 | / |
| 152 | D2156 | M | 84 | Nasopharyngeal Swab | Tuberculosis, post-operative multiple-drug resistance | C | > 40 | > 40 | / |
| 153 | D2157 | M | 57 | Nasopharyngeal Swab | Lung Shadow | C | > 40 | > 40 | / |
| 154 | D2158 | M | 65 | Nasopharyngeal Swab | Chronic HBV | C | > 40 | > 40 | / |
| 155 | D2159 | M | 44 | Nasopharyngeal Swab | Tuberculosis, Drug-induced liver damage | C | > 40 | > 40 | / |
| 156 | D2160 | M | 37 | Nasopharyngeal Swab | Fever to be tested | C | > 40 | > 40 | / |
| 157 | D2161 | F | 28 | Nasopharyngeal Swab | Fever to be tested | C | > 40 | > 40 | / |
| 158 | D2162 | M | 21 | Nasopharyngeal Swab | Fever to be tested | C | > 40 | > 40 | / |
| 159 | D2163 | M | 40 | Nasopharyngeal Swab | Fever to be tested | C | > 40 | > 40 | / |
| 160 | D2164 | M | 75 | Nasopharyngeal Swab | Fever to be tested | C | > 40 | > 40 | / |

| | | | | | | | | | |
|-----|-------|---|----|---------------------|---|---|------|------|---|
| 161 | D2165 | M | 35 | Nasopharyngeal Swab | Abdominal distention to be tested | C | > 40 | > 40 | / |
| 162 | D2166 | F | 52 | Nasopharyngeal Swab | Liver Cirrhosis | C | > 40 | > 40 | / |
| 163 | D2167 | M | 49 | Nasopharyngeal Swab | HBV | C | > 40 | > 40 | / |
| 164 | D2168 | M | 51 | Nasopharyngeal Swab | Upper Gastrointestinal Bleeding | C | > 40 | > 40 | / |
| 165 | D2169 | F | 63 | Nasopharyngeal Swab | Paravertebral Abscess | C | > 40 | > 40 | / |
| 166 | D2170 | M | 63 | Nasopharyngeal Swab | AIDS, Lung Infection, Headache to be tested | C | > 40 | > 40 | / |
| 167 | D2171 | M | 23 | Nasopharyngeal Swab | Lung Shadow, | C | > 40 | > 40 | / |
| 168 | D2172 | M | 25 | Nasopharyngeal Swab | Cough to be tested | C | > 40 | > 40 | / |
| 169 | D2173 | F | 30 | Nasopharyngeal Swab | Lung Shadow | C | > 40 | > 40 | / |
| 170 | D2174 | M | 66 | Nasopharyngeal Swab | Tuberculosis | C | > 40 | > 40 | / |
| 171 | D2175 | F | 26 | Nasopharyngeal Swab | Tuberculosis | C | > 40 | > 40 | / |
| 172 | D2176 | M | 55 | Nasopharyngeal Swab | Tuberculosis | C | > 40 | > 40 | / |
| 173 | D2177 | M | 35 | Nasopharyngeal Swab | AIDS, fever to be tested | C | > 40 | > 40 | / |
| 174 | D2178 | F | 23 | Nasopharyngeal Swab | Fever | C | > 40 | > 40 | / |
| 175 | D2179 | M | 50 | Nasopharyngeal Swab | Fever to be tested | C | > 40 | > 40 | / |
| 176 | D2180 | M | 39 | Nasopharyngeal Swab | Fever to be tested | C | > 40 | > 40 | / |
| 177 | D2181 | M | 40 | Nasopharyngeal Swab | Fever to be tested | C | > 40 | > 40 | / |
| 178 | D2182 | M | 81 | Nasopharyngeal Swab | Fever to be tested | C | > 40 | > 40 | / |
| 179 | D2183 | M | 64 | Nasopharyngeal Swab | Fever to be tested | C | > 40 | > 40 | / |
| 180 | D2184 | M | 29 | Nasopharyngeal Swab | Fever to be tested | C | > 40 | > 40 | / |
| 181 | D2185 | M | 10 | Nasopharyngeal Swab | Fever to be tested | C | > 40 | > 40 | / |
| 182 | D2186 | M | 36 | Nasopharyngeal Swab | Pleural Effusion | C | > 40 | > 40 | / |
| 183 | D2187 | M | 23 | Nasopharyngeal Swab | Fever to be tested | C | > 40 | > 40 | / |
| 184 | D2188 | F | 34 | Nasopharyngeal Swab | Fever to be tested | C | > 40 | > 40 | / |
| 185 | D2189 | F | 31 | Nasopharyngeal Swab | Pharyngitis | C | > 40 | > 40 | / |
| 186 | D2190 | M | 57 | Nasopharyngeal Swab | Fever to be tested | C | > 40 | > 40 | / |
| 187 | D2191 | M | 69 | Nasopharyngeal Swab | Lung Infection? | C | > 40 | > 40 | / |
| 188 | D2192 | M | 21 | Nasopharyngeal Swab | Acute Tonsillitis | C | > 40 | > 40 | / |

| | | | | | | | | | |
|-----|-------|---|----|---------------------|---|---|------|------|---|
| 189 | D2193 | F | 39 | Nasopharyngeal Swab | URTI? | C | > 40 | > 40 | / |
| 190 | D2194 | F | 16 | Nasopharyngeal Swab | Pharyngitis | C | > 40 | > 40 | / |
| 191 | D2195 | F | 38 | Nasopharyngeal Swab | Pharyngitis | C | > 40 | > 40 | / |
| 192 | D2196 | M | 31 | Nasopharyngeal Swab | Lung Infection, Fever | C | > 40 | > 40 | / |
| 193 | D2197 | M | 80 | Nasopharyngeal Swab | Asthma to be tested | C | > 40 | > 40 | / |
| 194 | D2198 | M | 73 | Nasopharyngeal Swab | Community Acquired Pneumonia | C | > 40 | > 40 | / |
| 195 | D2199 | F | 47 | Nasopharyngeal Swab | Chest tightness to be tested | C | > 40 | > 40 | / |
| 196 | D2200 | M | 61 | Nasopharyngeal Swab | HIV, Primary Liver Cancer | C | > 40 | > 40 | / |
| 197 | D2205 | F | 54 | Nasopharyngeal Swab | Lung Infection, Fever | C | > 40 | > 40 | / |
| 198 | D2206 | M | 59 | Nasopharyngeal Swab | Rhinitis | C | > 40 | > 40 | / |
| 199 | D2207 | M | 88 | Nasopharyngeal Swab | Rhinitis | C | > 40 | > 40 | / |
| 200 | D2208 | F | 53 | Nasopharyngeal Swab | Bronchial Asthma | C | > 40 | > 40 | / |
| 201 | D2209 | M | 64 | Nasopharyngeal Swab | HBV, Lung Infection | C | > 40 | > 40 | / |
| 202 | D2210 | M | 82 | Nasopharyngeal Swab | Community Acquired Pneumonia | C | > 40 | > 40 | / |
| 203 | D2211 | M | 65 | Nasopharyngeal Swab | Foreign body in bronchus? | C | > 40 | > 40 | / |
| 204 | D2212 | M | 83 | Nasopharyngeal Swab | Community Acquired Pneumonia, non-severe | C | > 40 | > 40 | / |
| 205 | D2213 | M | 46 | Nasopharyngeal Swab | Chronic HBV, fever | C | > 40 | > 40 | / |
| 206 | D2214 | M | 51 | Nasopharyngeal Swab | Cough to be tested | C | > 40 | > 40 | / |
| 207 | D2215 | F | 77 | Nasopharyngeal Swab | Renal Pelvis Tumor, Acute Gastroenteritis | C | > 40 | > 40 | / |
| 208 | D2216 | F | 30 | Nasopharyngeal Swab | Ectopic Pregnancy | C | > 40 | > 40 | / |
| 209 | D2217 | F | 62 | Nasopharyngeal Swab | HIV, Cervical Cancer | C | > 40 | > 40 | / |
| 210 | D2218 | M | 72 | Nasopharyngeal Swab | Community Acquired Pneumonia | C | > 40 | > 40 | / |
| 211 | D2219 | F | 82 | Nasopharyngeal Swab | COPD with acute exacerbation | C | > 40 | > 40 | / |
| 212 | D2220 | F | 88 | Nasopharyngeal Swab | Fever to be tested? Severe malnutrition | C | > 40 | > 40 | / |
| 213 | D2221 | F | 29 | Nasopharyngeal Swab | Cough to be tested | C | > 40 | > 40 | / |
| 214 | D2222 | F | 34 | Nasopharyngeal Swab | Community Acquired Pneumonia, non-severe | C | > 40 | > 40 | / |
| 215 | D2223 | F | 59 | Nasopharyngeal Swab | Diabetes | C | > 40 | > 40 | / |
| 216 | D2224 | F | 36 | Nasopharyngeal Swab | HBV, Early Intrauterine Pregnancy | C | > 40 | > 40 | / |

| | | | | | | | | | |
|-----|-------|---|----|---------------------|------------------------------|---|------|------|---|
| 217 | D2226 | F | 55 | Nasopharyngeal Swab | Community Acquired Pneumonia | C | > 40 | > 40 | / |
| 218 | D2229 | M | 84 | Nasopharyngeal Swab | Lung Infection | C | > 40 | > 40 | / |

dewei 德维